Managing diabetes has never offered more therapeutic options. Continuous glucose monitors (CGMs), automated insulin delivery systems, GLP-1 receptor agonists, SGLT2 inhibitors, and individualized treatment plans have transformed patient care. Yet despite these advances, many people with diabetes continue to struggle, not because treatments are ineffective, but because the overall workload …
Read More »The Return of C-Peptide: Why This Old Biomarker Is Finding New Clinical Uses
For many years, C-peptide testing was viewed as a simple tool to distinguish type 1 diabetes from type 2 diabetes. However, the story has changed. As researchers gain a better understanding of pancreatic beta-cell function, C-peptide testing in diabetes has become much more valuable than a diagnostic aid alone. Today, …
Read More »Why Blood Sugar Changes Every Month: Using CGM to Manage Luteal Phase Insulin Resistance
Many women with diabetes notice that blood sugar levels become harder to control during certain weeks of the month. Despite eating the same meals, taking the same insulin doses, and maintaining consistent activity levels, glucose readings may suddenly climb. This recurring pattern is often linked to luteal phase insulin resistance, …
Read More »The End of Sliding-Scale Insulin? How Predictive AI Is Transforming Inpatient Diabetes Care
Hospital glucose management has long relied on reactive treatment strategies, especially sliding-scale insulin protocols that respond to blood glucose after it has already risen. While this approach remains common, healthcare systems are increasingly exploring AI solutions for inpatient diabetes care that predict glucose changes before they become dangerous. Instead of …
Read More »Could “Smart” Insulin End Hypoglycemia? The Race Toward Glucose-Responsive Therapy
For more than a century, insulin has saved millions of lives. Yet despite remarkable advances in diabetes technology, one major challenge remains: preventing hypoglycemia while maintaining excellent glucose control. That is why researchers are developing glucose-responsive insulin, often called “smart” insulin. Instead of delivering a fixed amount of insulin regardless …
Read More »After CGM, Is Continuous Lactate Monitoring the Next Big Breakthrough?
Continuous glucose monitoring (CGM) has fundamentally changed diabetes management by giving patients and clinicians access to real-time glucose data. As a result, treatment decisions have become more precise, and many people with diabetes now spend more time within their target glucose range. However, glucose represents only one part of the …
Read More »Does It Matter When Your Patients Eat? The New Science of Chrono-Nutrition
For decades, diabetes management has focused on what patients eat and how much they consume. However, emerging research suggests another factor deserves attention: when they eat. The growing field of chrono-nutrition research in diabetes explores how meal timing interacts with the body’s internal clock to influence glucose metabolism, insulin sensitivity, …
Read More »Beyond A1C: Could Metabolic Flexibility Become the Next Major Diabetes Biomarker?
For decades, A1C has served as the gold standard for assessing long-term glucose control in people with diabetes. However, it tells only part of the story. Researchers are now exploring whether metabolic flexibility could become an important biomarker in diabetes, offering a deeper understanding of metabolic health than A1C alone. …
Read More »Should Patients Still Be Using Flash CGM? Navigating the Shift to Real-Time Monitoring
As diabetes technology continues to evolve, clinicians are increasingly faced with an important question: should patients still be using flash continuous glucose monitoring (CGM), or is it time to switch to real-time CGM? While flash CGM systems have significantly improved glucose monitoring and patient engagement over traditional fingerstick testing, real-time …
Read More »A Positive Type 1 Diabetes Screen Isn’t Always Equal: Why IA-2 Changes the Risk Calculation
As population-based screening for type 1 diabetes (T1D) becomes more common, clinicians increasingly encounter positive islet autoantibody results in children and adults who have no symptoms. However, not all positive screening results carry the same clinical significance. A single positive autoantibody may indicate elevated risk, yet the specific antibody detected …
Read More »
Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.